NCT04969315View on ClinicalTrials.gov

TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

June 23, 2023

Primary Completion Date

June 1, 2026

Study Completion Date

December 31, 2027

Conditions
Renal Cell CancerCastrate Resistant Prostate CancerNon Small Cell Lung CancerHead and Neck Squamous Cell CarcinomaColorectal Cancer (CRC)Endometrial CancerOvarian Cancer
Interventions
DRUG

TT-10

TT-10 orally administered BID

DRUG

TT-4

TT-4 is orally administered QD

Trial Locations (3)

40241

RECRUITING

Norton Cancer Institute, Louisville

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

90033

RECRUITING

USC Norris Comprehensive Cancer Center, Los Angeles

Sponsors

Lead Sponsor

Portage Biotech
All Listed Sponsors
lead

Portage Biotech

INDUSTRY

NCT04969315 - TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors | Biotech Hunter | Biotech Hunter